Journal Article

DKFZ-2017-04286

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.

Schlenk, R. F. ; Kayser, S. ; Bullinger, L. ; Kobbe, G. ; Casper, J. ; Ringhoffer, M. ; Held, G. ; Brossart, P. ; Lübbert, M. ; Salih, H. R. ; Kindler, T. ; Horst, H. A. ; Wulf, G. ; Nachbaur, D. ; Götze, K. ; Lamparter, A. ; Paschka, P. ; Gaidzik, V. I. ; Teleanu, V. ; Späth, D. ; Benner, A.DKFZ* ; Krauter, J. ; Ganser, A. ; Döhner, H. ; Döhner, K. ; Group, G. A. S. (Collaboration Author)

2014
HighWire Press Stanford, Calif.

This record in other databases:  

Please use a persistent id in citations: doi:10.1182/blood-2014-05-578070

Abstract: The objective was to evaluate the prognostic and predictive impact of allelic ratio and insertion site (IS) of internal tandem duplications (ITDs), as well as concurrent gene mutations, with regard to postremission therapy in 323 patients with FLT3-ITD-positive acute myeloid leukemia (AML). Increasing FLT3-ITD allelic ratio (P = .004) and IS in the tyrosine kinase domain 1 (TKD1, P = .06) were associated with low complete remission (CR) rates. After postremission therapy including intensive chemotherapy (n = 121) or autologous hematopoietic stem cell transplantation (HSCT, n = 17), an allelic ratio ≥ 0.51 was associated with an unfavorable relapse-free (RFS, P = .0008) and overall survival (OS, P = .004); after allogeneic HSCT (n = 93), outcome was significantly improved in patients with a high allelic ratio (RFS, P = .02; OS, P = .03), whereas no benefit was seen in patients with a low allelic ratio (RFS, P = .38; OS, P = .64). Multivariable analyses revealed a high allelic ratio as a predictive factor for the beneficial effect of allogeneic HSCT; ITD IS in TKD1 remained an unfavorable factor, whereas no prognostic impact of concurrent gene mutations was observed. The clinical trials described herein were previously published or are registered as follows: AMLHD93 and AMLHD98A, previously published; AML SG 07-04, ClinicalTrials.gov identifier #NCT00151242.

Keyword(s): FLT3 protein, human ; fms-Like Tyrosine Kinase 3

---

Contributing Institute(s):

1. Biostatistik (C060)

Research Program(s):

1. 313 - Cancer risk factors and prevention (POF3-313) (POF3-313)

Appears in the scientific report 2014

---

Database coverage:
; BIOSIS Previews ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Ebsco Academic Search ; IF >= 10 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection

---